Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN SODIUM versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN SODIUM versus PROFENAL.
IBUPROFEN SODIUM vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category D/X
Category C
NSAID
NSAID